Ascendis Pharma A/S (ASND) — AI 주식 분석

Name: ASND 재무 데이터
Creator: Stock Expert AI
License: https://www.stockexpertai.com/terms

이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

Ascendis Pharma A/S(ASND)는 헬스케어 섹터에서 사업을 운영하며, 최근 주가는 $261.23, 시가총액은 $16.2B입니다. 펀더멘털, 기술적, 심리 요인 전반에서 90/100의 높은 신뢰도 점수를 기록합니다.

빠른 답변

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs. Their key product is SKYTROFA, used for treating patients with growth hormone deficiency (GHD).

주요 정보: 가격: $261.23 일일 변동: +0.16% 시가총액: $16.2B 애널리스트 목표가: $320.27 (2026년 9월 11일) 목표가 상승여력: +22.6% MoonshotScore: 90/100 섹터: 헬스케어 거래소: NASDAQ

MoonshotScore는 투명한 0-100 등급입니다. 미국 상장 보통주는 사업 품질, 재무 안전성, 밸류에이션, 성장 지속성, 모멘텀의 5대 축에 걸쳐 섹터 동종 기업과 비교해 점수가 매겨지며, ETF, OTC 및 해외 상장 종목은 9개 시그널 레거시 모델을 사용합니다. 이는 금융 조언이 아닌 교육 및 심층 실사를 위해 만들어졌습니다. 방법론

기업 개요

요약:

Ascendis Pharma A/S is a biopharmaceutical company specializing in TransCon technology to create sustained-release therapies, primarily focused on endocrinology and 종양학.

Their lead product, SKYTROFA, addresses growth hormone deficiency, positioning them as a key player in innovative drug delivery within the competitive biotechnology sector.

ASND는 무엇을 하는 회사인가요?

Ascendis Pharma A/S, founded in 2006 and headquartered in Hellerup, 덴마크, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies that address unmet medical needs.

The company's core technology, TransCon, enables the creation of sustained-release drugs by temporarily linking an inactive drug to a carrier molecule. This approach aims to improve efficacy, safety, and patient convenience. Ascendis Pharma's lead product, SKYTROFA (lonapegsomatropin-tcgd), is approved for the treatment of pediatric growth hormone deficiency (GHD). SKYTROFA offers a once-weekly dosing regimen, providing a significant advantage over daily injections required by traditional growth hormone therapies. Beyond SKYTROFA, Ascendis Pharma is developing a pipeline of TransCon-based therapies targeting various diseases, including hypoparathyroidism and achondroplasia. The company's geographic focus is global, with commercial operations in 북미, 유럽, and 일본. Ascendis Pharma competes with established pharmaceutical companies in the endocrinology and 종양학 spaces, differentiating itself through its innovative TransCon technology and focus on sustained-release therapies.

ASND의 투자 테제는 무엇인가요?

Ascendis Pharma presents a 매력적인 investment opportunity based on its innovative TransCon technology and the commercial success of SKYTROFA. The company's revenue is expected to grow significantly as SKYTROFA gains further 시장 침투 and expands into new geographies. The ongoing development of TransCon PTH for hypoparathyroidism and TransCon CNP for achondroplasia represents substantial growth 촉매제. However, the company's negative 순이익률 of -31.7% and high 주가수익비율(P/E) of -53.27 indicate potential risks related to profitability and valuation. Investors should closely monitor the 임상시험 results of pipeline candidates and the 경쟁 환경 to assess the 장기 성장 potential of Ascendis Pharma. The company's 베타 of 0.48 suggests lower 변동성 compared to the overall market.

ASND는 어떤 산업에서 운영되고 있나요?

Ascendis Pharma operates within the biotechnology industry, which is characterized by high growth potential and intense competition. The market for growth hormone deficiency therapies is estimated to be worth billions of dollars annually.

Key trends in the industry include the development of novel drug delivery systems and personalized medicine. Ascendis Pharma's TransCon technology positions it favorably in this landscape, allowing for the creation of sustained-release therapies that offer improved patient convenience and efficacy. Competitors include companies like BioMarin Pharmaceutical Inc. (BMRN) and Exelixis, Inc. (EXEL), which are also developing innovative therapies for various diseases.

바이오테크놀로지

헬스케어

ASND의 성장 기회는 무엇인가요?

Expansion of SKYTROFA into new geographies: Ascendis Pharma has the opportunity to expand the commercialization of SKYTROFA into additional markets beyond 북미, 유럽, and 일본. This geographic expansion could significantly increase revenue and 시장 점유율. The global market for growth hormone deficiency therapies is estimated to be worth several billion dollars, providing ample opportunity for growth. Timeline: Ongoing, with potential for expansion into new markets within the next 2-3 years.
Development and commercialization of TransCon PTH for hypoparathyroidism: TransCon PTH is a promising therapy for hypoparathyroidism, a rare endocrine disorder. The market for hypoparathyroidism therapies is estimated to be worth hundreds of millions of dollars annually. Successful development and commercialization of TransCon PTH could generate significant revenue for Ascendis Pharma. Timeline: Ongoing 임상시험, with potential for 규제 승인 and commercial launch within the next 3-5 years.
Advancement of TransCon CNP for achondroplasia: TransCon CNP is being developed for the treatment of achondroplasia, a genetic disorder that causes dwarfism. The market for achondroplasia therapies is estimated to be worth hundreds of millions of dollars annually. Positive 임상시험 results and 규제 승인 could lead to substantial 매출 성장 for Ascendis Pharma. Timeline: Ongoing 임상시험, with potential for 규제 승인 and commercial launch within the next 3-5 years.
Pipeline expansion into 종양학: Ascendis Pharma is developing TransCon toll like receptors 7/8 agonist and TransCon IL-2 ß/g for intratumoral and systemic delivery, respectively. These programs represent a significant opportunity to diversify the company's pipeline and enter the rapidly growing 종양학 market. The global 종양학 market is worth hundreds of billions of dollars annually. Timeline: 초기 단계 development, with potential for 임상시험 within the next 1-2 years.
Strategic partnerships and collaborations: Ascendis Pharma can pursue strategic partnerships and collaborations with other pharmaceutical companies to accelerate the development and commercialization of its pipeline products. These partnerships could provide access to additional resources, expertise, and markets. Timeline: Ongoing, with potential for new partnerships to be announced at any time.

시가총액 of $16.2Billion, reflecting investor confidence in the company's growth prospects.
매출총이익률 of 86.3%, indicating strong 가격 결정력 and efficient manufacturing processes.
SKYTROFA approved for pediatric growth hormone deficiency (GHD), providing a significant 수익원.
TransCon technology platform enabling the development of sustained-release therapies.
Negative 주가수익비율(P/E) of -53.27 due to current losses, requiring careful monitoring of future profitability.

ASND는 어떤 제품과 서비스를 제공하나요?

Develops therapeutics for unmet medical needs.
Offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
Develops TransCon Growth Hormone (hGH) for pediatric GHD in 일본.
Develops TransCon hGH for adults with GHD.
Develops TransCon parathyroid hormone for adult hypoparathyroidism.
Develops TransCon CNP for pediatric achondroplasia.
Develops TransCon toll like receptors 7/8 agonist for intratumoral delivery.
Develops TransCon IL-2 ß/g for systemic delivery.

ASND는 어떻게 수익을 창출하나요?

Develops proprietary drugs using TransCon technology.
Out-licenses or co-develops certain products.
Generates revenue through sales of SKYTROFA and potential future products.
Focuses on endocrinology and 종양학 therapeutic areas.

Patients with growth hormone deficiency (GHD).
Patients with hypoparathyroidism.
Patients with achondroplasia.
Healthcare providers who prescribe Ascendis Pharma's products.

Proprietary TransCon technology platform.
Strong 지식재산권 protection.
First-mover advantage in sustained-release growth hormone therapy.
Established commercial 인프라 for SKYTROFA.

ASND 주가를 상승시킬 수 있는 요인은 무엇인가요?

Upcoming: Potential FDA 승인 of TransCon PTH for hypoparathyroidism (expected in 2026).
Upcoming: 임상시험 results for TransCon CNP in achondroplasia (expected in late 2026).
Ongoing: Continued commercial expansion of SKYTROFA in existing markets.
Ongoing: Initiation of 임상시험 for TransCon 종양학 programs.
Ongoing: Announcement of new strategic partnerships or collaborations.

ASND의 주요 리스크는 무엇인가요?

Potential: 임상시험 failures for pipeline products.
Potential: Regulatory setbacks or delays.
Ongoing: Competition from established pharmaceutical companies and biosimilars.
Potential: Product liability claims.
Ongoing: 환율 리스크 due to fluctuations in the exchange rate between the U.S. dollar and the Danish Krone.

ASND의 핵심 강점은 무엇인가요?

Innovative TransCon technology platform.
Approved product (SKYTROFA) with strong clinical data.
Experienced 경영진.
Strong 지식재산권 portfolio.

ASND의 약점은 무엇인가요?

Reliance on a single approved product (SKYTROFA).
Negative profitability.
High 연구개발(R&D) expenses.
Competition from established pharmaceutical companies.

회사 프로필

CEO: Jan Moller Mikkelsen
본사: Hellerup, DK
직원 수: 1,017
IPO 연도: 2015

AI 인사이트

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapeutics for unmet medical needs. Their key product is SKYTROFA, used for treating patients with growth hormone deficiency (GHD).

ADR Level: 2
ADR Ratio: 1:1

ASND의 경쟁사는 누구인가요?

ASND를 가격, 시가총액, AI MoonshotScore 기준으로 5개 동종 업체와 비교합니다。

회사	가격	변동	시가총액	MoonshotScore
RVMD Revolution Medicines, Inc.	$203.35	-2.08%	$43.2B	56
ROIV Roivant Sciences Ltd.	$40.66	-0.68%	$29.4B	—
MRNA Moderna, Inc.	$136.62	+0.74%	$54.2B	30
GH Guardant Health, Inc.	$159.03	-2.30%	$21.3B	35
EXEL Exelixis, Inc.	$56.20	-2.14%	$14.1B	98

AI 점수 제공: Stock Expert AI · 가격 데이터: FMP / Yahoo Finance

재무

기본 분석 스냅샷

매출 성장률 (회계연도)

+90.2%

순이익 성장률 (회계연도)

+42.1%

EPS 성장률 (회계연도)

+44.6%

자유 현금 흐름 성장률 (회계연도)

+114.2%

P/E (TTM)

18.61

유동비율

1.0

FMP 재무 데이터 및 정량적 분석 기반 · FY 2025

애널리스트 컨센서스

컨센서스 목표가: $320.27 (2026년 9월 11일)상승 여력: +22.6%

Financial Modeling Prep가 집계한 ASND의 종합 매수/보유/매도 추천.

경영진

CEO: Jan Moller Mikkelsen

질문 및 답변

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a biopharmaceutical company that utilizes its proprietary TransCon technology to develop and commercialize therapies for unmet medical needs, primarily in endocrinology and 종양학.

Their lead product, SKYTROFA, is a once-weekly growth hormone therapy for pediatric growth hormone deficiency (GHD).

What do analysts say about ASND stock?

애널리스트 컨센서스 on Ascendis Pharma A/S (ASND) is generally positive, reflecting optimism about the company's growth prospects and innovative TransCon technology. Key valuation metrics, such as 시가총액 and 매출 성장, are closely monitored.

Analysts consider the successful commercialization of SKYTROFA and the progress of pipeline products as key drivers of future growth.

What are the main risks for ASND?

Ascendis Pharma faces several risks inherent to the biotechnology industry. 임상시험 failures for pipeline products represent a significant risk, as positive results are crucial for 규제 승인 and commercial success.

Regulatory setbacks or delays could also impact the company's growth prospects. Competition from established pharmaceutical companies and the potential emergence of biosimilars pose a threat to SKYTROFA's 시장 점유율.

How does Ascendis Pharma A/S navigate 규제 승인 processes?

Ascendis Pharma navigates 규제 승인 processes by conducting rigorous 임상시험 to demonstrate the safety and efficacy of its therapies.

The company works closely with regulatory agencies, such as the FDA in the 미국 and the EMA in 유럽, to ensure compliance with all applicable regulations.

What are the key 성장 기회 for ASND in healthcare?

Ascendis Pharma's key 성장 기회 in healthcare lie in expanding its presence in endocrinology and 종양학. The company can expand SKYTROFA's 시장 점유율 in the growth hormone deficiency market by increasing awareness and improving access to the therapy.

The development and commercialization of TransCon PTH for hypoparathyroidism and TransCon CNP for achondroplasia represent significant growth drivers.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.

분석 중인 다른 종목

모든 주식 보기 →